Investigación e Informes

A Northwestern Medicine study found that adding GLP‑1 drugs such as semaglutide, tirzepatide or liraglutide to antihypertensive therapy increased incidents of dizziness, fainting and low‑blood‑pressure events.

Ventoscity's coin-sized VENTOs wearable, attached to underwear, measures intestinal hydrogen gas to objectively assess probiotic and prebiotic efficacy, marking a shift to data-driven gut health management.

The UK Medicines and Healthcare products Regulatory Agency invites participation in a Yellow Card Biobank study to examine genetic factors behind side effects of direct‑acting oral anticoagulants and allopurinol.

Japanese researchers found intermittent fasting reshapes gut microbiota and safeguards brain myelin, easing depression‑like behavior from chronic stress.

A study suggests valproate use by men near conception may be linked to higher risk of neurodevelopmental disorders in offspring.

Migraine prevalence in Korea is estimated at 6.5%, with women three times more affected than men.

Verastem Oncology reports modest updated results for its approved first‑line metastatic pancreatic cancer regimen of avutometinib plus defactinib and will redirect primary R&D resources to other pipeline candidates.

Two separate hacking rings accessed confidential Novo data and allegedly tried to extort the company for multi‑million‑dollar ransom payments.

The Pharmaceuticals and Medical Devices Agency (PMDA) held a workshop on New Approach Methodologies (NAMs) following the ICCR‑20 symposium.

The Pharmaceuticals and Medical Devices Agency (PMDA) has signed a Memorandum of Understanding with the London School of Hygiene & Tropical Medicine to promote joint work in pharmaceutical research and regulatory science.

The Pharmaceuticals and Medical Devices Agency (PMDA) has refreshed the One-Stop Service Platform page for ENSEMBLExJ, providing updated information for stakeholders.

Astellas Pharma's mirabegron study for overactive bladder in China is completed. The study evaluated efficacy and safety of mirabegron.